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Abstract
Drug metabolism or more generally, xenobiotic metabolism, is the biotransfor-
mation of exogenous compounds by living organisms, usually through specialized 
enzymatic systems. The metabolism of experimental therapeutics is an important 
aspect of pharmacology and translational medicine as the rate and the interindivid-
ual variability of drug metabolism can determine the duration and/or efficacy of a 
drug’s pharmacologic action. Since the introduction of metabolites in safety testing 
guidance by the Food and Drug Administration, major changes have occurred in 
the experimental methods for the identification and quantification of metabolites, 
evaluation of metabolites, and the timing of critical nonclinical studies to generate 
this information.
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1. Introduction
Drug metabolism is a drug-clearing event from systemic circulation influencing 
efficacy and toxicity in humans and preclinical species. The primary endpoints of 
enzymatic metabolism studies in both the drug discovery and preclinical stages are 
to resolve metabolic stability, identify and quantify primary metabolites, identify 
metabolic routes, and measure the potential for drug–drug interactions (DDI) [1]. 
The majority of in vivo and in vitro drug metabolism assessments center around 
hepatic models as the liver is the main metabolizing organ; however, drug metabo-
lism does occur in other organs and tissues (e.g., lungs, kidneys, and intestine). As 
a result, drug discovery and preclinical development investigations include evalua-
tion of drug metabolism in both hepatic and extra-hepatic models.
Over the past several decades in vitro and in vivo methodologies to quantita-
tively measure the absorption, distribution, metabolism, and excretion (ADME) 
properties of a chemical entity have matured to the point to where these properties 
can be reliably modeled and simulated in order to predict the general disposition 
of the chemical entity (or class of molecules) across multiple species and into 
humans [2]. As a result, approximations of oral bioavailability (F), total systemic 
clearance (CL), volume of distribution (Vd), and half-life (t1/2) can be predicted 
and subsequently evaluated. These intrinsic properties of the chemical entity with 
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consideration of the physiological processes can be used to assess the disposition of 
single and multiple dose escalation studies, identify potentially saturable hepatic 
pathways, and assess the formation of metabolites. From this information, potential 
DDIs can be predicted and investigated.
In order to effectively utilize the drug metabolism and pharmacokinetic 
(DMPK) information generated from in vitro and in vivo studies, it is important to 
have a proper understanding of when in the development timeline the data should 
be generated. Additionally, a thorough understanding of the clearance mechanism 
of a chemical entity can help lessen the need for some downstream in vivo stud-
ies potentially saving the pharmaceutical organization hundreds of thousands of 
dollars. While the timing of specific investigations may change due to the nature 
of the chemical entity being tested, the following general DMPK chronology and 
endpoints should be considered during discovery and development [3, 4]. The 
bullets relating to drug metabolism are bolded for emphasis and will be expanded in 
greater detail in the following pages.
1. Lead Selection (Hit-to-Lead; 100s to 1000s of compounds across multiple 
chemical series)
• Plasma protein binding, red blood cell partitioning, and intestinal perme-
ability (Caco-2) assessments
• In vitro metabolic stability screening using hepatocytes, microsomes,  
and S9 fractions
• In vivo rodent PK studies
• Investigate the in vitro:in vivo correlation (IVIVC) of CL and t1/2 and identify 
the series with problematic kinetics (e.g., high CL or low t1/2)
• Identification of the relevant tissues where the chemical entity and metabo-
lites may be sequestered
2. Optimization (Lead series identified and evaluated; <100 compounds)
• Pharmacokinetic studies in rodent and nonrodent species
• Identification of clinically relevant DDIs (In vitro assessment of P450 
induction and P450 inhibition)
• Screening Cocktail DDI Study
• In vitro soft spot analysis/metabolic identification to identify metaboli-
cally liable sites on investigated chemical entities
• Drug transporter and tissue sequestration assessments
• Pharmacokinetic-Pharmacodynamic (PK-PD; exposure-effect) modeling
3. Drug Candidate Selection (< 5 compounds evaluated)
• Mass balance study in rodents and nonrodents in order to support 
 nonrodent toxicology species selection
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• Allometric scaling to predict human t1/2 and exposures in order to identify the 
starting dosages to be evaluated in the Phase 1 first-in-human (FIH) trials.
• Evaluation of DDIs
• Metabolite profiling of high dose blood samples near the peak whole 
blood/plasma concentrations from the repeat-dose toxicity studies.
4. Metabolite Safety Testing (Post FIH and concurrent with Phase 2 trials)
• Human specific metabolites or metabolites with exposures at higher 
levels in humans than in any of the animal test species are assessed in 
preclinical species.
2. Lead selection
During the Lead Selection stage of drug discovery, candidate chemical series and 
potential lead compounds are screened for preferential physiochemical properties 
and metabolic stability. Promising chemical entities are then investigated in vivo in 
rodents (N = 3-5) via cassette dosing [5] in order to generate PK data. With recent 
advances in microsampling techniques [6] and automated blood sampling systems 
[7], robust PK data can be generated in a limited number of rodents resulting in 
reliable IVIVC models. Pharmacokinetic data can then be predicted across multiple 
species to evaluate and identify the chemical series and chemical entities that are 
ideal candidates for optimization.
Most chemical entities are substrates of in vivo enzymatic metabolic reactions 
that modify the chemical structure to clear the exogenous compound over time. 
Metabolizing enzymes are primarily expressed in the liver but are also found in 
the intestines, lungs, and other various organs. Traditionally, there are two phases 
of drug metabolism that exist to transfrom lipophilic compounds into hydrophilic 
products that are more readily eliminated from systemic circulation. Phase 1 
biotransformations are primarily oxidative; however, reduction, hydrolysis, and 
hydration reactions are also observed. Phase 1 reactions are primarily carried out 
by microsomal expressed cytochrome P450s (CYP450), flavin monooxygenases, 
aldehyde oxidase, and monoamine oxidase in the hepatocytes and microsome 
preparations from hepatocytes (a fragment of endoplasmic reticulum and attached 
ribosomes obtained by the centrifugation of homogenized cells). Phase 2 biotrans-
formations are conjugative and occur within the S9 fractions (harvested from a 
mixture of unfractionated microsomes and cytosol by the centrifugation [9000 g] 
of homogenized cells) and hepatocytes. The primary conjugative reactions are 
glucuronidation, sulfation, methylation, acetylation, glutathione conjugation, and 
amino acid conjugation.
2.1 Metabolic stability
The industry standard for screening the metabolic stability of a compound or 
compound-series is via the substrate depletion approach and the determination 
of half-life in rodent, nonrodent and human. Briefly, the metabolic stability, or 
intrinsic clearance (Clint) is assessed by incubating the compound at a concentra-
tion assumed to be below the Km for P450 metabolism. The in vitro Clint can be 
assessed in multiple species hepatocytes, hepatic S9 fractions and/or microsomes 
[8]. A series of samples are collected and analyzed over the time course in order to 
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determine the percentage of compound remaining. The resulting half-life (t1/2) is 
then appropriately converted to an activity (Clint, mg/mL/Kg), taking into account 
the ratio of protein content to liver mass (e.g., mammalian microsomal protein, 
45 mg protein/gm liver), and the ratio of liver mass to total animal or body mass 
(e.g., human, 20 gm/Kg body weight); the principles of allometry apply in this 
context of scaling protein content and P450 activity (physiological parameter) 
versus organ-to-body mass ratio (anatomical parameter) [9]. The intrinsic clear-
ance in vitro PK parameter may be generated from a number of subcellular frac-
tions, including microsomes, S9 fraction, cytosol and mitochondria (e.g., MAO 
metabolism), as well as from whole cell incubations employing freshly isolated or 
cryopreserved hepatocytes. The high throughput nature of the aforementioned 
metabolic stability assay enables the rapid generation of in vitro PK parameters  
(t1/2 and Clint) with each cycle of medicinal chemistry. With the continued innova-
tion of mass spectroscopy and the liquid chromatogram coupled mass spectrometry 
(LC/MS) bioanalytical techniques, the contemporary biotransformation laboratory 
and scientist can now identify metabolites in the same intrinsic clearance assay, 
thus elucidating the relevant pathway of metabolism under kinetically controlled 
conditions. Alternatively, the same subcellular fraction and whole cell metabolism 
experiment may be employed to determine all relevant pathways and under condi-
tions where compound(s) concentrations have been elevated appreciably above the 
anticipated KM for a particular drug metabolizing enzyme (DME). The merits of 
either approach will be discussed in a subsequent section.
2.2 Soft spot analysis/metabolite identification
The medicinal chemist utilizes the metabolic stability data generated during the 
Lead Selection and Lead Optimization stages of discovery as a tool to understand 
the impact of structural modifications within one or more chemical series or a 
lead series, respectively. Depending on the subcellular fraction employed, the 
Clint informs the chemist as to ensuing stabilization of the compound or series to 
oxidative (or reductive) metabolism via P450 (e.g., microsomes or S9 fractions). In 
addition to the t1.2 and Clint data produced from in vitro screening, the incubations 
also provide an opportunity to determine the site of metabolism on the molecule, 
or elucidate the so-called metabolic “soft-spot”. From P450 mediated oxidation, to 
direct glucuronidation and sulfation, to ester and amide hydrolysis, small molecule 
drug candidates possess physico-chemical properties that are perfectly suited to 
drug metabolism-mediated, hepatic clearance. Typically, the soft-spot analysis 
is performed in the same subcellular fraction or hepatocyte system employed in 
the intrinsic clearance assessment. With recent improvements in electrospray 
ionization liquid chromatography tandem mass spectrometry (ESI-LC–MS/MS) 
bioanalysis, the DMPK scientist is able to associate one or more predominate sites of 
metabolism (e.g., oxidation, reduction, hydrolysis, conjugation) with the clear-
ance of a compound or series in vitro, and under the same kinetically controlled 
conditions of the metabolic stability assessment (i.e., ≤ 1 μM). The described 
soft-spot analysis construct enables a concerted execution of both the Clint assess-
ment (substrate depletion) as well as the identification of the principal metabolites 
produced in vitro in “one plate”. Whether in concert with the Clint assessment or as a 
discrete stand-alone in vitro experiment, innovation in mass spectroscopy hardware 
and software has enabled significant means of metabolite detection and structural 
elucidation, the results of which commonly augment the nonclinical pharmacology 
reports and summaries within an Investigational New Drug application (IND).
Still, the DMPK scientist may seize on the opportunity to determine the 
soft-spot(s) of metabolism to simultaneously assess the extent and range of 
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biotransformation likely produced in multiple species during preclinical and  clinical 
development. Access to study samples (e.g., plasma, urine, bile, feces, organ tissue) 
presents the opportunity to survey the metabolites produced in the rodent and 
nonrodent species selected for development, comparing to that observed in human 
hepatocytes and hepatic (e.g.) subcellular fractions. In order to provide a compara-
tive analysis to the in vivo metabolism picture, the DMPK scientist will produce in 
parallel a set of in vitro experiments in rodent and nonrodent, where the compound 
or preclinical candidate is incubated at concentrations assumed to exceed the Km 
for most drug metabolizing enzymes (e.g., ≥25 μM ≤50 μM). Importantly, in vitro 
incubations of subcellular fractions should be fortified with appropriate cofac-
tors (or co-enzymes) to “fuel” the relevant catalytic activities of select enzymes 
and at excess (1-2 mM): P450 (NADPH, or NADPH-regenerating system), FMO 
(NADPH), UGT (UDPGA), SULT (PAPS), NAT (acetyl-CoA), GST (GSH).
2.3 In vivo-in vitro correlation
The in vitro hepatic clearance of a compound (within a series) is a valuable 
PK parameter for the medicinal chemist and the DMPK scientist. Because the 
intrinsic clearance (Clint, mL/min/kg) describes the unrestricted, unscaled clear-
ance of a compound, the medicinal chemist may utilize Clint to gauge the impact 
of structural alterations in the series on P450 metabolism (oxidation or reduction 
in microsomes); the primary goal of which to stabilize a compound or chemical 
series towards hepatic clearance, thus increasing the in vitro half-life. The value of 
the Clint PK parameter is in its correlation to a plasma clearance (CLp), as typically 
determined in a rodent (e.g., Sprague–Dawley rat) or nonrodent (e.g., beagle dog) 
species during the hit-to-lead and later in the lead optimization stages of discovery. 
Establishing an in vitro:in vivo correlation (IVIVC) between predicted hepatic 
clearance (CLH) and CLp serves two purposes: (1) validation of the CLint screening 
approach for the ensuing lead optimization stage of discovery, and (2) establishes 
the nonclinical species for in vivo PK screening and the species predictive of human 
hepatic clearance. The selection of appropriate in vitro and in vivo PK screening 
approaches during early discovery provides a mechanism for an iterative medicinal 
chemistry optimization of one or more chemical series, with the goal of predicting 
human PK parameters.
3. Lead optimization
Once a lead series is selected, further in vitro and in vivo testing is conducted 
on a fewer number of compounds, illuminating metabolism and PK (and pharma-
cologic) attributes for select compounds. This stage of drug discovery is known as 
Lead Optimization. From an in vitro perspective, potential DDIs are identified with 
CYP450 inhibition and induction assays, and reaction phenotyping assays. Soft 
spot analysis is performed to identify areas liable to biotransformation, metabolic 
identification of potential in vivo metabolites, and drug transporters are identified 
for which the candidate entities are a substrate. Rodent and nonrodent PK studies 
are conducted in order to optimize the exposure and disposition (PK) of the lead 
series while determining the nonclinical pharmacologic effects of the lead series 
in select rodent and/or nonrodent disease models. These data are then used to 
establish preliminary exposure-effect relationships (PK-PD). The exposure data 
collected from rodent (e.g.) models of efficacy are particularly valuable and provide 
a critical assessment of dose-exposure relationships of the lead series in anticipa-
tion of advancing into the single- and repeat-dose tolerability assessments prior to 
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candidate selection. At minimum this exposure information guides the discovery 
team to the dose range required for a tolerability screening assessment; ideally, the 
efficacy model exposure assessments guide the selection of the dosing frequency 
required to maintain exposure during the repeat-dose tolerability assessment.
The Food and Drug Administration’s (FDA) January 2020 guidance on clinical 
drug interaction studies states that “clinically relevant DDIs between an investiga-
tional drug and other drugs should therefore be: (1) defined during drug develop-
ment as part of the sponsor’s assessment of the investigational drug’s benefits and 
risks; (2) understood via nonclinical and clinical assessment at the time of the inves-
tigational drug’s approval; (3) monitored after approval; and (4) communicated in 
the labeling.” Furthermore, the FDA defines the goals of studies that evaluate P450 
enzyme- and transporter-mediated DDIs to be: (1) determine whether the inves-
tigational drug alters the pharmacokinetics of other drugs; (2) determine whether 
other drugs alter the pharmacokinetics of the investigational drug; (3) determine 
the magnitude of changes in pharmacokinetic parameters; (4) determine the clinical 
significance of the observed or expected DDIs; and (5) inform the appropriate 
management and prevention strategies for clinically significant DDIs [10].
Additionally, the FDA also provided guidance for in vitro drug interaction stud-
ies (P450 and transporter) in January 2020. This guidance provides the framework 
for designing and conducting in vitro experiments in order to assess potential clini-
cal DDIs. The CYP450 experiments are to: (1) determine which CYP450 enzyme 
the drug entity is a substrate of (reaction phenotyping); (2) determine if the drug 
entity is a CYP450 inhibitor; and (3) determine if the drug entity is a CYP450 
inducer. Metabolite investigations may be warranted on a case-by-case basis. If the 
metabolite is pharmacologically active and contributes ≥50% of the overall activity, 
then reaction phenotyping analyses should be conducted. Inhibition studies are to 
be conducted if the total exposure/area under the curve (AUC) of the metabolite 
is ≥25% of the parent or if the metabolite is more polar than the parent entity and 
the AUC of the metabolite is greater than or equal to the parent. Transporter studies 
are to investigate if the drug entity is a substrate of efflux pumps (P-glycoprotein 
[P-gp] and breast cancer resistance protein [BCRP]), hepatic transporters 
(OATP1B1 and OATP1B3), and renal transporters (OAT, OCT, and MATE) [11].
3.1 Reaction phenotyping
Having assembled relative in vitro pharmacokinetic data (e.g., Clint) and eluci-
dated metabolism pathways for a compound or preclinical candidate, it’s incumbent 
upon the DMPK scientist to identify the particular human drug metabolizing 
enzymes that are contributing to the in vitro clearance in an effort to identify and/
or manage latent drug–drug interaction potential that exist. To identify such victim 
drug–drug interaction (DDI) potential, [12] the DMPK scientist employs a variety 
of recombinantly expressed drug metabolizing enzymes, notably P450 enzymes to 
determine the extent any one enzyme contributes to the clearance of a compound 
[13]. The fraction-metabolized (fm) term is often employed within the context 
of P450 mediated metabolism, but more recently applied to the growing number 
preclinical candidates observed to be non P450 substrates (e.g., UGT). Correlating 
the in vitro microsomal (e.g.) clearance to contributions from any one or more P450 
enzymes, most notably P450 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4, is the goal 
of so-called reaction phenotyping. Importantly, this reaction phenotyping of drug 
clearance involves the comparative metabolism (and intrinsic clearance thereof) 
of the preclinical compound by the recombinant enzyme to what is observed in 
the subcelluar fraction; in the case of P450 or UGT, that can be accomplished in 
hepatic microsomes or S9 fractions. Two industrial standard approaches involve the 
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generation of relative activity factors (RAF method) and intersystem extrapolation 
factors (ISEF) to adequately relate a single recombinant enzyme activity to human 
liver microsomes bearing a full complement of expressed P450 enzymes. Each of 
these methods, while instrumental in arriving at the fm value for a particular drug 
candidate, fall short in estimating the impact of polymorphically expressed enzymes 
(e.g., P450 2D6, 2C9, 2C19, UGT1A1) in the metabolism-mediated clearance of a 
compound. More recently, and as a result of pharmacogenomics and pharmacoge-
netics clinical research and impact, the DMPK scientist can gain access to subcellular 
fractions obtained from sparse or densely genotyped individual liver donors.
The importance of linking a particular biotransformation reaction to one or 
more metabolites is of particular interest during preclinical development. Whether 
in terms of pharmacology (e.g., P450 mediated production of an active metabolite), 
drug safety (e.g., UGT mediated production of an acyl glucuronide) or confirming 
multiple enzymes producing the same pathway (e.g., risk mitigation of a clinically 
relevant DDI), the use of recombinantly expressed enzymes are critical in mapping 
the range of metabolites observed in human hepatocytes or subcellular fractions 
to specific drug metabolizing enzymes. At the elevated concentrations employed 
in the generation of metabolite(s) in vitro, there is limited kinetic value to these 
experiments and should be viewed as informative in nature and restricted to the 
metabolite ID and structure elucidation exercise previously described.
3.2 CYP450 inhibition studies
Once the metabolic pathways are identified, in vitro P450 inhibition and induc-
tion studies are conducted in order to predict clinically significant DDIs. Per the 
FDA’s January 2020 guidance, “The sponsor should evaluate an investigational drug’s 
potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A in both a reversible manner (i.e., reversible inhibition) and time-dependent 
manner (i.e., time-dependent inhibition (TDI))” [14].
In general, each microsomal assay includes the preparation of both test com-
pound and positive control samples in order to assess the metabolite formation 
specific to each CYP450 isoform. Experiments are typically prepared with both the 
test compound at increasing concentrations and a selective P450 probe substrate 
prepared at a predetermined concentration that will produce first-order kinetics. 
Following an incubation under physiologic conditions (pH and temperature), 
the experiment is quenched and resulting incubations are prepared for analysis 
employing LC–MS/MS. The data is then analyzed by comparing the metabolite 
formation of the test samples relative to the control samples and dose–response 
plots are created to determine the specific endpoints of the assay.
3.3 Screening DDI cocktail assay
Concurrent with the early optimization stage P450 assessments, a cocktail of 
the test compound and substrates that exclusively bind to specific P450 isoforms 
is incubated with human liver microsomes across multiple concentrations of 
the test compound. Following incubation, P450 isoform specific metabolites are 
measured in each sample and compared to a control sample. Based on the metabo-
lite abundance of the test samples relative to the control sample, as measured by 
liquid chromatography and tandem mass spectrometry (LC–MS/MS), a potential 
DDI liability can be identified early to inform future in vitro and potentially future 
in vivo investigations. Based on the results of this screening assay and the P450 
inhibition and induction assays, definitive in vitro DDI screening may be warranted 
during the Drug Candidate Selection stage.
Drug Metabolism
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3.4 CYP450 induction studies
CYP induction is typically measured in vitro using three separate lots of human 
hepatocytes. A metabolically active human hepatocyte cell line (e.g. HepaRG) can 
sometimes be substituted for one of the human hepatocyte lots. Three P450s are 
commonly measured for induction – CYP1A2, 2B6 and 3A4. If CYP3A4 induction 
is observed, it is recommended to assess CYP2C8, 2C9 and 2C19 induction in a 
separate experiment. For the induction experiment, human hepatocytes are incu-
bated in a sandwich culture format prior to the experiment. The media is changed 
to serum-free prior to the start of the experiment in order to lower the basal expres-
sion of CYPs. On day one, test compounds are added and incubated with the cells 
for 48-72 hours, with daily replenishment of media and test compound. Induction 
can be assessed by either measuring mRNA levels or activity levels. For the mRNA 
method, the cells are harvested after 48 hours, mRNA is extracted and the expres-
sion level of CYPs is measured by qPCR. For the activity assay, specific substrates 
for each of the CYPs are added following 72 hours of incubation and the rate of 
metabolism is measured over a defined time point, e.g. 2 hours. A positive result is 
considered to be ≥2-fold increase over the vehicle control.
3.5 Membrane drug transporters
Membrane drug transporters play an important role in the uptake, distribution 
and elimination of both endogenous substances and drugs in the body. Because 
they help regulate the flux of many substances across cell membranes they are 
often implicated in detoxification mechanisms, multidrug resistance and clinical 
DDIs [15]. Drug transporters control the concentration of drug substrates avail-
able for P450 reactions by regulating drug disposition within the cell for both the 
parent drug and metabolites. Drug metabolizing enzymes are often coupled with 
transporters to efficiently modify the level of drug present in a specific tissue. A 
well-known example of this is the efficient removal of bilirubin from plasma by 
OATP1B1-mediated uptake into the liver, UGT1A1-mediated formation of mono- 
and diglucuronide metabolites and subsequent elimination into the bile via the 
MRP2 transporter. In addition, the expression levels of drug metabolism enzymes 
are closely tied to transporters. For example, the nuclear receptor PXR regulates the 
expression of both drug metabolism enzymes such as CYP3A4 and CYP2C9 as well 
as several efflux drug transporters including P-gp and MRP2.
Membrane transporters relevant to drug development include two major super-
families – ATB-binding cassette (ABC) and solute carrier (SLC). Members of the 
ABC superfamily utilize ATP hydrolysis to actively transport a solute across a cell 
membrane against a concentration gradient. The most relevant ABC transporters 
include P-glycoprotein (P-gp, MDR1), breast cancer resistance protein (BCRP) and 
multidrug resistance-associated protein 2 (MRP2). One of the primary functions 
of these transporters is to efflux small molecule substrates out of the cell in order 
to reduce cellular exposure and protect cells and organs against potentially harmful 
drugs or toxins. They are widely expressed in the epithelia of the intestine, liver and 
kidney, and in the endothelium of the blood–brain barrier and other blood-tissue 
barriers where they are localized on apical membranes.
In contrast, members of the SLC superfamily utilize solute exchange mecha-
nisms to drive drug transport, including endogenous anions/cations or electrogenic 
mechanisms. SLC transporters include the major uptake transporters such as 
organic anion (OAT, OATP), organic cation (OCT) and the multidrug and toxin 
extrusion transporters (MATE1, MATE2-K). OATP1B1 and OATP1B3 are located 
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primarily on the hepatocyte plasma-facing apical membrane, while OAT1, OAT3 
and OCT2 are located on the basolateral membrane of the kidney proximal tubule. 
MATE1 and MATE2-K are located both in the proximal tubule and in the liver 
(canalicular membrane).
Several of the ATP and SLC transporters have been implicated in clinical DDIs 
and the FDA has focused on the following list as relevant for in vitro screening: 
P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2-K. In 
vitro evaluation of specific transporter interactions can employ a variety of tools 
including human and animal monolayer systems, transfected cell lines with single 
or multiple transporters over-expressed and membrane vesicles, along with a panel 
of substrates and inhibitors as control probes (Table 1).
3.5.1 Monolayer systems
The standard assay format for transporter function involves measuring the 
permeability of a test article through a confluent monolayer of cells grown on a per-
meable membrane. The cells and membrane are part of a transwell insert which fits 
into a normal 24-well plate, thus creating two media chambers. The upper reservoir 
is referred to as the apical (or A) chamber while the lower is the basolateral (or B) 
chamber. Addition of test article to each reservoir in separate wells, allows measure-
ment of the apparent permeability in both directions (A to B, and B to A). The cell 
line used, therefore, must have the ability to form tight junctions between cells to 
prevent leakage of test article through the monolayer, and must express the trans-
porters in a polarized fashion, enabling measurement of transport of substrates 
in two directions. Two cell lines are commonly used in this format – Caco-2 and 
MDCKII. The Transwell format is used not only to measure the permeability of the 
test article in a single direction, but also determine the efflux ratio, calculated as the 
ratio of permeability in both directions (B to A/A to B). If the efflux ratio is greater 
than 2, an interaction with a transporter is probable and needs further study.
Caco-2 cells were originally derived from a human colorectal adenocarcinoma. 
Although the cells originated from the human colon, they are widely used as a 
model of intestinal absorption and transporter activity [16]. When placed in 
culture, these cells undergo differentiation to an intestinal phenotype. The cells are 
characterized by a well-defined apical brush border, formation of tight junctions, 
and the endogenous expression of the majority of uptake and efflux transporters 
normally present in intestinal enterocytes [17]. Caco-2 cells are regarded as the 
most sophisticated in vitro tool for medium to high throughput modeling of drug 
transport across human plasma/tissue barriers.
A non-human alternative cell line that is also widely used in monolayer studies 
is MDCKII (Madin-Darby canine kidney strain II). A number of MDCKII cell lines 
Assay Cell system Endpoint
Permeability 
Assessment




Caco-2, MDCK, membrane vesicles, 








Examples of in vitro systems to investigate transporter-mediated drug interactions.
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have been generated with single or double human transporters transfected into 
the cells. These modified animal cell lines enable the study of individual human 
transporters in the absence of competition from other human transporters. One 
caveat with MDCK cells is that there is an active form of canine P-gp present that is 
functionally similar to the human form and needs to be accounted for when trans-
porter data is analyzed.
Other animal cell lines used for transporter studies include LLC-PK1 (porcine) 
and Chinese hamster ovary (CHO) cells.
3.5.2 Membrane vesicle assays
An alternative to cell-based transporter assays involves membrane vesicles, 
in which the assay is conducted with membrane preparations from baculovirus-
infected insect cells or mammalian cells that have been transfected with the trans-
porter of interest. When isolated, a small portion of the membrane vesicles end up 
in an inverted configuration (“inside-out”) and are particularly useful for studying 
efflux transporters. Transporter activity (activation or inhibition) can be assessed 
by either measuring uptake of a substrate into the vesicles over time, or by measur-
ing ATPase activity.
3.5.3 Genetically modified cell lines
Transporters recognize and interact with of a broad range of compounds, and 
each transporter has been characterized for their physicochemical preferences in 
substrates [18]; however, there remains a large overlapping area of substrate recog-
nition between transporters. Some of the current ambiguity in assigning specificity 
toward a single transporter is due to the use of different cellular systems to define 
the interaction. Small molecule inhibitors are commonly used to define transporter 
interactions, but inhibitors often show overlapping interactions between transport-
ers [19]. Novel test systems that avoid the use of small molecule inhibitors may be 
able to improve our ability to unambiguously identify specific substrate interactions 
Two approaches have recently been used to address this situation. Knockdown 
of transporter gene expression can be accomplished using small inhibitory RNA 
(siRNA). Alternatively, complete gene knockout can be accomplished using zinc 
finger nucleases (ZFNs) or Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR). For example, several individual or dual knockout cell lines were 
recently developed in the C2BBe1 cell line (a subclone of Caco-2) and are com-
mercially available [20]. In addition, the canine P-gp transporter in MDCK cells has 
recently been knocked out.
4. Drug candidate selection
Following the investigations of the Lead Optimization stage, the pharmaceuti-
cal organization should have weaned their list of promising drug candidates to 
less than five entities. From a drug metabolism perspective, there are three major 
investigations that occur: (1) ADME profiling in rodents and nonrodent species; 
(2) definitive in vitro DDI screening and potentially in vivo confirmatory investiga-
tions; and (3) metabolite profiling in the identified toxicology species. By the end of 
the Drug Candidate Selection stage, the pharmaceutical organization should have 
all the information they need to support their Investigational New Drug application 
(IND) or Exploratory IND application.
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4.1 Mass balance study
Due to the high expense, complete ADME profiling (non-radiolabeled) does not 
typically occur until a strong candidate for IND submission has been identified. The 
in vitro metabolism, tissue distribution analyses, and in vivo PK studies performed 
in the prior development stages are used to inform the investigators regarding the 
potential route of clearance, the tissues to be collected and quantitated, and if a 
major metabolite should be investigated as part of the study. The goals of these 
studies are to definitively identify the route of elimination (including biliary excre-
tion), assess tissue distribution, and if applicable, characterize metabolite exposure 
relative to parent exposures. The animals in these studies are typically split into 
two groups where one group has their bile duct cannulated in order to assess biliary 
excretion from the liver. The animals are individually housed in metabolism cages 
that collect the urine and feces excreted by each animal. Depending on the study 
design, each animal may be sacrificed at various time points in order to assess criti-
cal tissues for exposure to the drug entity.
4.2 DDI evaluation
Based on the results of the P450 inhibition/induction assays and the screen-
ing DDI studies, specific P450 isoforms are further investigated in vitro for the 
DDI potential instead of a general cocktail approach as employed in the Lead 
Optimization stage. If an in vitro DDI is observed, an in vivo study is warranted to 
confirm if the DDI persists.
4.3 Metabolite profiling
At dose levels greater than 100 mg/kg, the primary clearance mechanism is typi-
cally saturated resulting in greater interaction between the drug entity and other 
P450 enzymes. Metabolite profiling analyses typically use blood samples collected 
at tox level doses greater than 100 mg/kg; ideally samples at or near the Cmax. The 
metabolites are typically identified early during the lead optimization stage in the 
soft spot/metabolite identification studies. The parent and metabolites are typically 
quantitated via LC–MS/MS methods. The end goal is to obtain the percent abun-
dance of each metabolite relative to the parent.
5. Metabolite safety testing
Following Phase 1 FIH studies, the blood samples at or near the Cmax from the 
high dose cohort of the multiple ascending dose study undergo metabolite profiling. 
The resulting metabolite abundancies are then compared to the preclinical metabo-
lite profiling studies in order to identify human only metabolites or metabolites that 
are present at higher plasma concentrations in humans than in the animals used in 
the preclinical studies. These metabolites are referred to as disproportionate drug 
metabolites. Per the FDA’s March 2020 guidance, “In general, these metabolites are 
of interest if they account for plasma levels greater than 10 percent of total drug-
related exposure, measured as area under the curve at steady state.” In the instance 
that a disproportionate meets these criteria, futher in vitro (genotoxicity) and in 
vivo (general toxicity and embryo-fetal development toxicity) studies are required 
to assess the safety of the metabolite. Typically, these studies can be conducted 
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6. Summary
Drug metabolism is a drug-clearing event from systemic circulation influencing 
efficacy and toxicity in humans and preclinical species. The primary endpoints of 
enzymatic metabolism studies in both the drug discovery and preclinical stages are 
to resolve metabolic stability, identify and quantify primary metabolites, identify 
metabolic routes, and measure the potential for DDIs and are used to predict human 
PK. The intrinsic kinetic properties of the chemical entity with consideration of the 
physiological processes can be used to assess the disposition of single and multiple 
dose escalation studies, identify potentially saturable hepatic and transporter 
pathways, and assess the formation of metabolites. From this information, potential 
DDIs are predicted and subsequently investigated.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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